CompletedPhase 4

Impact of Amantadine on Traumatic Brain Injury

Egypt50 participantsStarted 2020-09-30

Plain-language summary

The aim of this study is to evaluate whether the addition of amantadine to the management regimen of traumatic brain injury patients would have a favorable effect on recovery and neurological complications in association with prognosis biomarkers Interleukin-18 (IL-18), Neuron-specific enolase (NSE) and (Neurotensin).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

* Inclusion criteria •Adult patients will be enrolled if they present with clinical signs of trauma brain injury * Exclusion criteria * Age lower than 18 * Females with positive pregnancy test * Known congestive heart failure or ischemic heart disease * Any injury disturbs the examination (high cervical cord injury or locked-in syndrome, could be a source of bias) * Penetrating head trauma * Need for any operation (laparotomy or craniotomy) * Severe brain disease (For example CVA history or brain tumour) * Renal failure with GFR lower than 60 ml/min * Patients with unknown identity

What they're measuring

Neurotensin pg/ml

Timeframe: 2 weeks

Neuron specific enolase (NSE) ng/mL

Timeframe: 2 Weeks

interleukin-18 (IL-18) pg/ml

Timeframe: 2 Weeks

ICU stay (days)

Timeframe: 6 weeks

Trial details

NCT IDNCT04527289

SponsorDamanhour University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-01

View on ClinicalTrials.gov More Trauma, Brain trials